From the last Quarterly
European Medicines Agency Paediatric Investigation Plan (PIP) feedback received for ATL1102 in DMD As part of its review of the PIP, the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) provided feedback outlining additional information requirements on the Company’s planned Phase IIb clinical trial in non-ambulant DMD boys. ANP is addressing the PDCO information requirements and anticipates finalising the trial design with PDCO later in Q3’CY21, ahead of submitting the clinical trial application shortly thereafter for the Phase IIb trial of ATL1102 in non-ambulant DMD patients to be conducted in Europe.
- Forums
- ASX - By Stock
- PER
- Where others have failed will Atl1102 succeed ?
Where others have failed will Atl1102 succeed ?, page-405
-
- There are more pages in this discussion • 692 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
0.004(4.94%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.1¢ | 8.5¢ | 8.1¢ | $46.54K | 563.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 164616 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 100110 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 164616 | 0.081 |
3 | 143000 | 0.080 |
1 | 250000 | 0.079 |
3 | 71500 | 0.078 |
2 | 121300 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 100110 | 1 |
0.087 | 125000 | 1 |
0.089 | 102263 | 2 |
0.090 | 146175 | 1 |
0.091 | 108000 | 1 |
Last trade - 15.55pm 28/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online